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We have read with interest, the article by Deroux et al. [1],
describing the use of tocilizumab (TCZ) in refractory Behçet's
disease (BD), in which four female patients were treated success-
fully without any adverse event. In particular, mucocutaneous
lesions responded well to TCZ administration.
In addition to the letter to Editor written by Emmi et al. [2], the
mucocutaneous paradoxical effect of TCZ is well reported in other
diseases, such as rheumatoid arthritis and ankylosing spondylitis,
and in different portions of the gastrointestinal tract, involving oral
mucosa as well as small and large intestine [3,4]. In this regard we
report herein a patient affected by relapsing polychondritis (RP)
resistant to corticosteroid treatment that developed recurrent
mucosal ulcers after the second infusion of TCZ.
B.F. is a 46-year-old-man in which RP was diagnosed in 2009
for the presence of recurrent auricular and nasal chondritis, dry
cough, hoarseness, pain at proximal trachea and larynx, and a non-
erosive peripheral arthritis involving both hands and wrists and
the left knee. Acute phase reactants resulted highly elevated and
both rheumatoid factor and anti-citrullinated protein antibody
were negative. The patient had never suffered from mucosal
ulceration. The patient was at first treated with repeated bolus
corticosteroids and intramuscular methotrexate 15 mg/weekly,
with a weak control of the symptomatology. For this reason, in
2010 he started a therapy with infliximab (350 mg every 8 weeks,Fig. Major oral ulcers involving the oral mucos
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72/& 2016 Elsevier Inc. All rights reserved.augmented to 350 mg every 5 weeks) till June 2015, when
the drug was suspended for loss of efficacy and reappearance of
the symptomatology above mentioned. TCZ was started at a dose
of 8 mg/kg every 4 weeks in August, with a good initial response.
Since the second infusion, the patients started suffering from
recurrent major oral ulcers (Fig.); ulcers swabs twice demon-
strated the absence of Herpes viruses. An empirical 1-week
treatment with valaciclovir 1000 mg/tid did not ameliorate
the ulcers. Due to the persistence of oral ulcerations and,
since the 13th infusion, the onset of peripheral arthritis involving
both hands, the shoulders and the hips, TCZ was suspended
and ulcers progressively disappeared during the following
15 days.
In addition to the conflicting data about TCZ efficacy in
mucocutaneous manifestations of BD patients well summarized
by Emmi and colleagues and already reported by Diamantopoulos
[5], this biological agent seems to be associated independently
with gastrointestinal ulceration, and mouth ulcerations are
reported as common adverse reactions in TCZ data sheet. In fact,
several trials (STREAM, TOWARD, SATORI, SAMURAI, and OPTION)
reported a variable percentage ranging from 2% to 11.5% of “oral
ulcerations” and “stomatitis” in patients treated with TCZ, without
any clinical description or correlation with infections [6–10]
(Table). In addition to this, TCZ was associated with gastrointest-
inal perforation and Iwasa et al. [3] speculated that this condition
may be preceded by mucosal ulceration. The mechanism is
not clear, but it is probably mediated by inhibiting STAT3, which
promotes injury and impaired regeneration of intestinal
epithelium [11]. For this reason, TCZ-related mucosal ulcers seem
to be a general adverse effect more than an exacerbation of
mucocutaneous involvement as it can happen in BD. Ad hoca (A), the tongue (B) and the lower lip (C).
Table
Reported rates of tocilizumab-related stomatitis and/or oral ulcerations during some clinical trials
Study Patients Drugs Stomatitis/oral ulcers
STREAM [5] 54 Placebo 3.7%
54 TCZ 4 mg 5.6%
53 TCZ 8mg 7.3%
TOWARD [6] 414 Placebo þ DMARD Mouth ulceration 1%/stomatitis 0%
802 TCZ 8 mg þ DMARD Mouth ulceration 2%/stomatitis 1%
SATORI [7] 61 MTX 8 mg 0%
66 TCZ 8 mg 11.5%
SAMURAI [8] 148 DMARD 9.0%
158 TCZ 8 mg 5.7%
OPTION [9] 204 Placebo 0.5%
212 TCZ 4 mg 2%
206 TCZ 8 mg 2%
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